



August 05, 2026

To,

BSE Limited
25, P. J. Towers,
Dalal Street,
Mumbai – 400 001
Scrip Code: 500120

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra – Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: DIAMINESQ

Sub: Disclosure of Regulation 32(1) of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on June 30, 2026

Dear Sir/Ma'am,

Pursuant to the Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statement of deviation or variation of fund raised through preferential issue under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on June 30, 2026, is enclosed herewith.

Kindly take the above mentioned information on records.

Thanking You,

Yours Faithfully,
For Diamines and Chemicals Limited

Hemaxi Pawar
Company Secretary
Membership No.: A52581
Encl: As above



Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Diamines And Chemicals Limited					
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others					
Date of Raising Funds	October 01, 2024 (Allotment of Warrants) & March 24, 2026 (Date of Allotment of Equity on conversion of Warrants)					
Amount Raised	₹ 50.58 Cr (100% of issue) *					
Report filed for Quarter ended	June 30, 2026					
Monitoring Agency	applicable / not applicable					
Monitoring Agency Name, if applicable	NA					
Is there a Deviation / Variation in use of funds raised	Yes / No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA					
If Yes, Date of shareholder Approval	NA					
Explanation for the Deviation / Variation	NA					
Comments of the Audit Committee after review	None					
Comments of the auditors, if any	None					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation (Rs in Crores)	Modified allocation, if any	Funds Utilised (Rs in Crores)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks
capital expenditures, working capital requirements, acquisition, investment in technology and for general corporate purpose	NA	12.51 Cr & 11.15 Cr	NA	12.51 Cr & 11.15 Cr*	-	Rs. 12.51 crores (i.e. 25% of the issue i.e. 9,06,390 convertible warrants @ Rs. 138 per warrant) and utilised for the quarter ended March 31, 2026 Rs. 11.15 crores (i.e. 75% of issue i.e. Rs. 414 per share) received and 2,69,402 equity shares allotted on 24.03.2026) and utilised for the quarter ended June 30, 2026



Deviation or variation means:

- (a) Deviation in the object or purposes for which the funds has been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in the terms of contract referred to in the funds raising documents i.e. prospectus, letter of offer, etc

*Note: The Company had received In-Principle approval on September 19, 2024 for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Board, in its meeting held on October 01, 2024, had allotted 906390 convertible warrants on receipt of subscription money Rs. 12.51 crores i.e. 25% of the total Issue, on preferential basis to the investors. Further, out of total issued 906390 warrants, the Company had made allotment of 2,69,402 equity shares (conversion of warrants issued on preferential basis), on receipt of exercise money Rs. 11.15 crores (75% of the issue) by passing board resolution at duly convened board meeting on March 24, 2026, to the applicant from whom entire money has been received and rest all warrants were lapsed as at March 31, 2026 (Last date of conversion of warrants into Equity Shares). Entire Fund has been utilised as on June 30, 2026.